Bioequivalence and Bioavailability Forum

In the Bioequivalence output in Phoenix WinNonlin "Partial tests" are given and so are "sequential tests" in tabs. The tests are described in the Users manual (see link) and below material from the manual. I am wondering which tab one would use in for regulatory report or would one submit both? There are very small differences in the numbers for a study I am working on (one of the subjects did not show up for the last period), whereas for another example of a 3 way crossover study I have (all subjects completed) for that example the partial and sequential data is exactly the same. My current is unbalanced on account of losing a subject.

http://screencast.com/t/lNW0Hiy8KG

from the manual:

Sequential Tests worksheet
The Sequential Tests worksheet is created by testing each model term sequentially.
The first model term is tested to determine whether or not it should enter
the model. Then the second model term is tested to determine whether or not it
should enter the model, given that the first term is in the model. Then the third model term is tested to determine whether or not it should enter the model, given that the first two terms are in the model. The model term tests continue until all model terms are exhausted.

Partial Tests worksheet
The Partial Tests worksheet is created by testing each model term given every
other model term. Unlike sequential tests, partial tests are invariant under the order in which model terms are listed in the Fixed Effects tab. Partial tests factor out of each model term the contribution attributable to the remaining model terms.
This is computed by modifying the basis created by the QR factorization to yield a basis that more closely resembles that found in balanced data.

Angus

---

Edit:Category changed. [Helmut]